title: Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet?
authors.affiliation: Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
authors.forename: H
authors.initials: H
authors.lastname: Lee
authors.affiliation: Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
authors.forename: P
authors.initials: P
authors.lastname: Duggan
authors.affiliation: Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
authors.forename: P
authors.initials: P
authors.lastname: Neri
authors.affiliation: Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
authors.forename: J
authors.initials: J
authors.lastname: Tay
authors.affiliation: Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
authors.forename: N J
authors.initials: NJ
authors.lastname: Bahlis
authors.affiliation: Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
authors.forename: V H
authors.initials: VH
authors.lastname: Jimenez-Zepeda
mesh_terms: D064591:Allografts; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D000075363:Immunoglobulin Light-chain Amyloidosis / Q000097:blood* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D018365:Neoplasm, Residual; D033581:Stem Cell Transplantation